Search Results - "Roethling, N."

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial by Lorenzen, S., Hentrich, M., Haberl, C., Heinemann, V., Schuster, T., Seroneit, T., Roethling, N., Peschel, C., Lordick, F.

“…Background: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but…”
Get full text

Cetuximab plus oxaliplatin leucovorin 5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) by Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, Peschel, C

“…Background: Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed the activity of cetuximab and chemotherapy in advanced…”
Get full text

Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I II trial by Lorenzen, S, Brücher, B, Zimmermann, F, Geinitz, H, Riera, J, Schuster, T, Roethling, N, Höfler, H, Ott, K, Peschel, C, Siewert, J R, Molls, M, Lordick, F

“…Oxaliplatin and 5-fluorouracil have a significant activity in locally advanced oesophageal squamous cell cancer (OSCC). However, their optimal dosage and…”
Get full text

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie by Lorenzen, S., Schuster, T., Porschen, R., Al-Batran, S.-E., Hofheinz, R., Thuss-Patience, P., Moehler, M., Grabowski, P., Arnold, D., Greten, T., Müller, L., Röthling, N., Peschel, C., Langer, R., Lordick, F.

“…This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma…”
Get full text

Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma : results of a phase 1/11 trial by LORENZEN, S, BRÜCHER, B, SIEWERT, J. R, MOLLS, M, LORDICK, F, ZIMMERMANN, F, GEINITZ, H, RIERA, J, SCHUSTER, T, ROETHLING, N, HÖFLER, H, OTT, K, PESCHEL, C

Get full text

Phase I trial of continous infusion 5-fluorouracil (CI-5FU) and escalating doses of oxaliplatin (OXA) given weekly with concurrent radiation (RT) in locally advanced esophageal squamous cell carcinoma (ESCC) by Brücher, B. L., Zimmermann, F., Riera, J., Becker, K., Roethling, N., Seroneit, T., Molls, M., Peschel, C., Siewert, J. R., Lordick, F.

“…Abstract only…”
Get full text

Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) by Lordick, F., Ott, K., Weber, W. A., Stein, H. J., Becker, K., Wieder, H., Roethling, N., Hennig, M., Peschel, C., Schwaiger, M., Siewert, J. R.

“…Abstract only…”
Get full text